​

ULUSLAR ARASI YAYINLARIM 

A1.Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators.N Engl J Med. 2022 Jan 19. doi: 10.1056/NEJMoa2108330. Online ahead of print.PMID: 35045221

 

 

A.2 Ruchan Uslu, Ulus A. Sanli, Canfeza Sezgin, Bulent Karabulut, Serdar B. Omay, Erdem Goker. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clinical Cancer Research, Dec; 6: 4958-4964, 2000.

​

 

A3. Safak Yuksel, Guray Saydam, Ruchan Uslu, Ulus Ali Sanli, Ender Terzioglu, Filiz Buyukececi, Serdar Bedii Omay. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leukemia Research, Apr; 26(4): 391-398, 2002.

 

A4. Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Guray Saydam, Serdar Bedii Omay, Erdem Goker. Which dosing scheme is suitable for the taxanes? An in vitro model. Archives of Pharmacal Research Aug; 25 (4): 550-5, 2002.

 

A4. Burak Z, Moretti JL, Ersoy O, Sanli U, Kantar M, Tamgac F, Basdemir G. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med. 2003 Sep;44(9):1394-401.

 

A5. Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Nur Selvi, Hakan H. Aydın, Guray Saydam, Erdem Goker, Serdar Bedii Omay. Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. Oncology Reports,  Nov-Dec; 10(6): 2083-8, 2003.

 

A6. Gülperi Öktem, Bulent Karabulut, Nur Selvi, Canfeza Sezgin, Ulus Ali Sanli, Ruchan Uslu, Mine Ertem Yurtseven, Serdar Bedii Omay. Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncology Research, 14: 381-386, 2004.

 

A7. Erdem Goker, Ulus Ali Sanli, Yildiray Yüzer, Ruchan Uslu, Bulent Karabulut, Ahmet Memis, Ahmet Coker, Ali Mentes. Bioembolisation for Unresectable Hepatocellular Carcinoma: Preliminary Results of a Translational Research Study. Journal of Experimental & Clinical Cancer Research, 23: 403-409, 2004.

 

A8. Karasulu HY, Karabulut B, Kantarci G, Ozgüney I, Sezgin C, Ulus Ali Şanlı, Göker E. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line. Drug Deliv. 2004 Nov-Dec;11(6):345-50.

 

A9. Ruchan Uslu, Ulus Ali Sanli, Yilmaz Dikmen, Bulent Karabulut, Aydin Ozsaran, Canfeza Sezgin, Gamze G. Muezzinoglu, Serdar B Omay, Erdem Goker. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. International Journal of Gynecologic Cancer, 15: 240245, 2005.

 

A10. Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Ulus Ali Sanli, Gamze Goksel, Osman Zekioglu, Necmettin Ozdemir, Erdem Goker. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. Journal of Chemotherapy, Feb; 17(1): 111-117, 2005.

A11. Bulent Karabulut, Canfeza Sezgin, Cosan M. Terek, Ruchan Uslu, Ulus Ali Sanli, Levent Akman, Aydin Özsaran, Yilmaz Dikmen, Erdem Göker. Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy, Oct; 51(6): 347-51. Epub 2005 Oct 14, 2005.

 

A12. Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Ulus Ali Sanli, Gamze Goksel, Yildiray Yüzer, Erdem Goker. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scandinavian Journal of Gastroenterology, Dec; 40(12): 1486-92, 2005.

 

A13. Terek, MC; Karabulut, B; Selvi, N; Akman, L; Karasulu, Y; Ozguney, I; Sanli, AU; Uslu, R; Ozsaran, A. Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line. International Journal of Gynecological Cancer, Mar-Apr; 16(2): 532-537, 2006.

 

A14. Ulus Ali Şanlı, Karabulut B, Uslu R, Korkut M, Goker E. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis. Medicinal Principles and Practice,  15(4): 288-92, 2006. (15 puan)

 

A15. N. Askar, T. Cırpan, E. Toprak, B. Karabulut, N. Selvı, M.C. Terek, R. Uslu, U.A. Sanlı & E. Goker. Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. International Journal of Gynecological Cancer, Jul-Aug; 16(4): 1552-6, 2006.

 

A16. Kucukzeybek Y, Gorumlu G, Karaca B, Erten C, Cengiz E, Kemal Gul M, Karabulut B, Uslu R,  Ulus Ali Şanlı, Goker E. Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer. Journal of B.U.ON Apr-Jun; 13(2): 199-203, 2008.

 

A17. Doganavsargil B, Argin M, Kececi B, Sezak M, Ulus Ali Şanlı, Oztop F. Secondary osteosarcoma arising in fibrous dysplasia, case report. Arch Orthop Trauma Surg. 2009 Apr;129(4):439-44. Epub 2008 Jun 17.

 

 

A18. Işikgoz Taşbakan M, Görümlü G, Pullukçu H, Ulus Ali Şanlı, Sipahi OR, Karabulut B, Tünger A. [A rare cause of catheter-related bacteremia: Rhizobium radiobacter] Mikrobiyol Bul. 2008 Apr;42(2):349-52.

 

A19. Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, Atmaca H, Uzunoglu S, Karabulut B, Ulus Ali Şanlı and Uslu R. Enhancement of Docetaxel-Induced Cytotoxicity and Apoptosis by All-Trans Retinoic Acid (ATRA) Through Downregulation of Survivin (Birc5), Mcl-1 and Ltbeta-R in Hormone- and Drug Resistant Prostate Cancer Cell Line, DU145.  Journal of Experimental& Clinical Cancer Research, Sep 12; 27(1): 37, 2008.

 

A20. Saydam BK, Goksel G, Korkmaz E, Zekioglu O, Kapkac M, Ulus Ali Şanlı, Uslu R, Sezgin C. Comparison of inflammatory breast cancer and noninflammatory breast cancer in Western Turkey. Medicinal Principles and Practice, 17(6): 475-80, 2008.

 

A21. Gorumlu G, Kucukzeybek Y, Kemal Gul M, Karaca B, Terek M. Cosan, Karabulut B, Ulus Ali Şanlı, Akman L, Ozsaran A, Dikmen Y, Uslu R. Pegylated liposomal doxorubucin in heavily pretreated epithelial ovarian cancer patients. Journal of B.U.ON, Jul-Sep; 13(3): 349-352, 2008.

 

A22. Karaca B, Kucukzeybek Y, Gorumlu G, Erten C, Gul MK, Cengiz E, Atmaca H, Uzunoglu S, Ulus Ali Şanlı, Karabulut B, Uslu R.  Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. European Cytokine Network, Dec; 19 (4): 176-84, 2008.

 

A23. Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Ulus Ali Şanlı, Baran Y, Uslu R. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biology International, Feb; 33(2): 239-46, Epub 2008 Dec 11, 2009.

 

 

 

A24. Cigdem Erten, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Mustafa K. Gul, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli and Ruchan Uslu. Regulation of growth factors in hormone and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. British Journal of Urology International, Jul; 104(1): 107-14, Epub 2009 Feb 3, 2009.

 

A25. Makay O, Gurcu B, Ulus Ali Şanlı, Zekioglu O, Oktay A, Goker E, Kapkac M. Complete response after chemotherapy in metastatic involvement of the orbita in breast cancer. Breast J. 2009 Jul-Aug;15(4):418-9. Epub 2009.

 

A26. Atmaca H, Gorumlu G, Karaca B, Degirmenci M, Tunali D, Cırak Y, Purcu DU, Uzunoglu S, Karabulut B, Ulus Ali Şanlı, Uslu R. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. Eur Cytokine Netw. 2009 Sep;20(3):121-30.

 

A27. Ulus Ali Şanlı, Gorumlu G, Erten C, Gul MK, Cengiz E, Kucukzeybek Y, Karaca B, Atmaca H, Uzunoglu S, Karabulut B, Uslu R.  Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. Cell Biol Int. 2009 Nov;33(11):1165-72.

 

A28. Ercument Cengiz, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Mustafa K. Gul, Cigdem Erten, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan. Overcoming drug resistance in hormone-and drug refractory prostate cancer cell line, PC-3 by a synergistic combination of docetaxel and gossypol. Mol Biol Rep. 2010 Mar;37(3):1269-77

 

A29.Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan Uslu. Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line, MCF-7.  J BUON. 2009 Jul-Sep;14(3):479-85.

 

 

A30. Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Ulus Ali Şanlı, Uslu R. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Med Oncol. 2010 Sep;27(3):585-91.

 

A31. Ozlem Akagunduz, Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus Ali Sanli, Ayfer Haydaroglu, Ruchan Uslu. Radiosensitization of Hormone-Refractory Prostate Cancer Cells by Gossypol Treatment. J BUON. 2010 Oct-Dec;15(4):763-7.

 

A32. Kucukzeybek Y, Gorumlu G, Cengiz E, Karabulut B, Sezgin C, Atmaca H, Ulus Ali Şanlı, Uzunoglu S, Uslu R. Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells. J Int Med Res. 2010 Sep-Oct;38(5):1663-72.

 

 

A33. Sezgin C, Gokmen E, Kapkac M, Zekioglu O, Esassolak M, Karabulut B, Ulus Ali Şanlı, Uslu R. p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma. Med Princ Pract. 2011;20(2):159-64.

A34. Karaca B, Atmaca H, Bozkurt E, Kisim A, Uzunoglu S, Karabulut B, Sezgin C, Ulus Ali Şanlı, Uslu R. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.. Mol Biol Rep. 2012 Dec 27. [Epub ahead of print]

A35. Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Ali Sanli U, Uslu R. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract. 2014 Sep 17. pii: 1078155214551315. [Epub ahead of print].

A36. 1. Varol U, Degirmenci M, Karaca B, Atmaca H, Kisim A, Uzunoglu S, Sezgin C, Ulus Ali Şanlı, Uslu R. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumour Biol. 2015 Feb;36(2):779-86. doi: 10.1007/s13277-014-2682-6

A37 . Arican A1, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Ulus Ali Şanlı, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer. 2014 Oct;22(10):2629-34. doi: 10.1007/s00520-014-2253-9. Epub 2014 Apr 22.

A38. Karaca B, Degirmenci M, Ozveren A, Atmaca H, Bozkurt E, Karabulut B, Ulus Ali Şanlı, Uslu R. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Cancer Chemother Pharmacol. 2015 Jun;75(6):1273-80. doi: 10.1007/s00280-015-2756-1. Epub 2015 Apr 30.

A39. Surmeli Z, Gursoy P, Erdogan AP, Bozkurt E, Atmaca H, Uzunoglu S, Sezgin C, Şanlı UA, Uslu R, Karaca B. Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway. Tumour Biol. 2015 Oct 13. [Epub ahead of print].

A40. Surmeli ZG, Varol U, Cakar B, Degirmenci M, Arslan C, Piskin GD, Zengel B, Karaca B, Ulus Ali Şanlı, Uslu R. Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncol Lett. 2015 Oct;10(4):2598-2602. Epub 2015 Jul 29.

A41.Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Ulus Ali Şanlı, Uslu R. Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.. J Oncol Pharm Pract. 2015 Aug;21(4):318-9. doi: 10.1177/1078155215585051. Epub 2015 May 15.

 

A42. The retrospective analysis of patients with uterine sarcomas: A single-center experience. Terek MC, Akman L, Hursitoglu BS, Ulus Ali Şanlı, Ozsaran Z, Tekindal MA, Dikmen Y, Zekioglu O, Ozsaran AA. J Cancer Res Ther. 2016 Jan-Mar;12(1):309-13. doi: 10.4103/0973-1482.148698.

 

A43. Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients. Akman L, Ertas IE, Gokcu M, Terek MC, Sanci M, Ulus Ali Şanlı, Zekioglu O, Ozsaran AA. J Cancer Res Ther. 2016 Jan-Mar;12(1):290-4. doi: 10.4103/0973-1482.158037

 

A44. Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway. Surmeli Z, Gursoy P, Erdogan AP, Bozkurt E, Atmaca H, Uzunoglu S, Sezgin C, Şanlı UA, Uslu R, Karaca B. Tumour Biol. 2016 Mar;37(3):3665-73. doi: 10.1007/s13277-015-3265-x.

​

Ulusal Yayınlarım

 

Ulus A. Şanlı. Kanserde Gen Tedavisi. Türk Hematoloji-Onkoloji Dergisi, 8(4): 245-251, 1998.

 

B4. Ulus A. Şanlı. Kanserin Metabolik etkileri. Aktuel Tıp Dergisi, 3(1): 71-74, 1998.

 

B5. Ulus A. Şanlı, Rüçhan Uslu, Erdem Göker. Nükleozid Analogları. Hematoloji-Onkoloji Güncel Derleme Dergisi2(1): 122-135, 1998.

 

B6. Erdem Göker, Ulus A. Şanlı. Hepatopankreotikobilier (HPB) Sistem Kanserleri Medikal Onkolojik Görüş. Türkiye Klinikleri Cerrahi Dergisi, 4(2): 106-110, 1999.

 

 

 

B8. Can Ceylan, İdil Ünal, Sezer Erboz, Ulus Şanlı. Bir İnflamatuar Meme Karsinomu Olgusu. T Klin Med Sci 20(6): 363-365, 2000. 

 

B9. Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker. Kolorektal Kanserlerde Kemoterapi. Hematoloji-Onkoloji Güncel Derleme Dergisi 2(2): 127-132, 2000. 

 

B10. Abdi Sağcan, Ulus Ali Şanlı, Banu Çiçek Bilkay. Testiste primer malign lenfoma: İki olgu nedeniyle. Türk Hematoloji-Onkoloji Dergisi 10(4): 222-224, 2000. 

 

B11. Rüçhan Uslu, Cem Cengiz, Ulus Ali Şanlı, V. Canfeza Sezgin, Güray Saydam, Bülent Karabulut, Funda Yılmaz, Gül Yüce, Tankut İlter, Serdar Bedii Omay, Erdem Göker. Hepatosellüler kanser tanısı konmuş hastalarda P53 mutasyonu sıklığı ve klinikopatolojik korelasyon. Türk Hematoloji-Onkoloji Dergisi 11(2): 82-87, 2001.

 

B12. Bülent Karabulut, Güray Saydam, Mustafa Özmen, Ulus ali Şanlı, Canfeza Sezgin, Mine Hekimgil, Rüçhan Uslu, Erdem Göker, Filiz Büyükkeçeci. Meme kanseri ve kronik lenfositik löseminin birlikte görülmesi: Olgu sunumu. Türk Hematoloji-Onkoloji Dergisi 11(2): 91-94, 2001.

 

B13. Tuncay Göksel, Serdar Soyer, Sezai Taşbakan, Ulus Ali Şanlı, Mahmut Ateş, Erdem Göker. Single-Agent Oral Etoposide in Patients With Relapsed orRefractory Extensive Small-Cell Lung Cancer. Turkish Respiratory Journal 3(1): 15-18, 2002.

 

B14. Ulus Ali Şanlı, Bülent Karabulut, Fatih tekin, V. Canfeza Sezgin, Güray saydam, Gamze Göksel Müezzinoğlu, Fahri Şahin, Rüçhan Uslu, Erdem Göker. Mide karsinomu seyrinde eozinofili: Olgu sunumu. Türk Hematoloji-Onkoloji Dergisi12(4): 206-209, 2002.

 

B15. Canfeza Sezgin, Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker. Arsenic Trioxide has Additive Cytotoxic Effect on MCF-7 Breast Cancer Cell Line With Taxanes. Turkish Journal of Medical Sciences 32(6): 439-444 2002.

 

B16. Serdar Bedii Omay, Güray Saydam, Hikmet Hakan Aydın, Nur Selvi, Gülperi Öktem, Ulus Ali Sanlı, Mahmut Tobu, Filiz Büyükkececi. Potential Involvement of Calcineurin in Regulating the State of Differentiation and  Apoptosis of HL-60 Cells During Methylprednisolone-Treatment. Turkish Journal of Haematology, Volume 20, No 3, Sayfa: 143-151, 2003. 

 

B17. V. Canfeza Sezgin, Ulus Ali Şanlı, Bülent Karabulut, Rüçhan Uslu, Gamze Göksel Müezzinoğlu, Erdem Göker, Necmettin Özdemir. Metastatik meme kanserinin tedavisinde capecitabine: etkinlik ve toksisite. Türk Hematoloji-Onkoloji Dergisi 13(4): 200-205, 2003.

 

B18. Bülent Karabulut, V. Canfeza Sezgin, Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker, Necmettin Özdemir, Selahattin Sanal. Meme kanserinde c-ErBb-2 ekspresyonu ve diğer prognostik faktörler ile ilişki var mı? Ege Tıp Dergisi 42(3): 161-165, 2003.

 

B19. V. Canfeza Sezgin, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker, Selahattin Sanal, Necmettin Özdemir. Meme kanserinde Ki-67 ekspresyonu ve diğer prognostik faktörler ile ilişkisi. Ege Tıp Dergisi 42(3): 173-177, 2003.

 

B20. Bülent Karabulut, Fatih Kırçelli, Veliddin C. Sezgin, Gamze G. Müezzinoğlu, Ulus A Şanlı, Rüçhan Uslu, Erhan Gökmen, Erdem Göker. Kemoterapi Sonrasında Gelişen Nekrotizan Miyofasiitis: Olgu Sunumu. Türk Hematoloji Onkoloji Dergisi 14(2): 99-104, 2004.

 

B21. Bülent Alkan, Bülent Karabulut, Veliddin C. Sezgin, Rüçhan Uslu, Ulus A Şanlı Necmettin Özdemir, Erdem Göker. Adjuvant Kemoterapi Uygulanmış Meme Kanserli Hastalarda Prognostik Faktörler. Türk Hematoloji Onkoloji Dergisi 14(3): 123-127, 2004.

 

B22. Erdem Göker, Ulus Ali Şanlı. Kolon Kanserinde Adjuvan Kemoterapi. Türkiye Klinikleri Cerrahi Dergisi  9(1): 81-85, 2004. . (SCI dışındaki uluslararası indekslerce taranan dergiler kapsamında)

 

B23. Ulus Ali Şanlı, Erdem Göker. Küçük Hücreli Akciğer Kanserinin Tedavisinde Kemoterapinin Yeri. Türkiye Klinikleri Göğüs Hastalıkları Dergisi  2(3): 262-268, 2004. .(SCI dışındaki uluslararası indekslerce taranan dergiler kapsamında)

 

B24. Ç. Erten, A. Memiş, T. Akalın, D. Sabah, G. Yücetürk, B. Karabulut, U. A.Şanlı, E Göker. Osteosarkomun Neo-Adjuvan Tedavisindeki Deneyimimiz.   İzmir Tepecik Eğitim Hastanesi Dergisi 15(3): 187-193, 2005. .

 

B25. Bülent Karabulut, Veliddin C. Sezgin, Gamze Göksel, Ulus A Şanlı, Rüçhan Uslu, Erdem Göker. Yüksek Riskli Malign Melanomun Adjuvan Tedavisinde Orta Yüksek Doz İnterferon Alfa-2B Tedavisinin Etkinliği ve Tolerabilitesi. Türk Hematoloji Onkoloji Dergisi 15(1): 6-14, 2005.

 

B26. Veliddin C. Sezgin, Bülent Karabulut, Rüçhan Uslu, Ulus A Şanlı, Erdem Göker. Daha önceden antrasiklin ve taksan tedavisi almış metastatik meme kanserli hastalarda gemsitabin tedavisi. Türk Hematoloji Onkoloji Dergisi 15(2): 68-72, 2005.

 

B27. Ulus Ali Şanlı. Meme Dernekleri Koordinasyon Kurulu (Mdkk) I. Ulusal Meme Kanseri Konsensus Toplantısı Sonuçları: Umkk Yerel İleri Evre Meme Kanseri Grubu. Meme Sağlığı Dergisi 3(1): 43-45, 2007. 

B28. Ulus Ali Şanlı. Kanseri Metabolik Etkileri ve Kaşeksi. Aktüel Tıp 12(3): 61-66, 2007.

B29. Yüksel Küçükzeybek, Gürbüz Görümlü, Şaziye Burçak Karaca, Ali Can Kazandı, Bülent Karabulut, Rüçhan Uslu, Ulus Ali Şanlı, Erdem Göker. Trastuzumab induced maculopapular skin reactions localized on the left fore arm and arm: a case report. Tıp Bilimleri Dergisi, Mayıs 2008 (yayın için kabul edildi).

B30. Ulus Ali ŞANLI. Chemotherapy in Male Genital Cancers: Prostate, Testicular and Penile Cancers Turkiye Klinikleri J Med Oncol-Special Topics 2011;4(1):193-7

B31. Ulus Ali Şanlı, Burcu Çakar. Kemik sarkomları tedavisinde kemoterapi, türkiye klinikleri. İskelet sistemi tümörleri özel sayısı 2012 (5)4 ,105-108

 

 

 

Bilimsel çalışmalarımız  onkoloji alanında hedefleyici tedaviler, immünoterapi, kanser aşıları, kemoterapi klinik araştırmaları devam etmektedir. 

​